← Insider Monitor
MeiraGTx Holdings plc logo
MGTX

MeiraGTx Holdings plc

Nasdaq · Biological Products, (No Diagnostic Substances)

2
Insider trades
0
Congress trades

Company Overview

A concise company profile alongside the latest public filing activity.

MeiraGTx Holdings plc develops gene therapies for inherited retinal diseases, neurodegenerative disorders, and other serious conditions, using viral vector-based delivery and a proprietary gene regulation technology platform. It also operates manufacturing facilities to produce gene therapy products for its own pipeline and for partners.

Industry
Biological Products, (No Diagnostic Substances)
Headquarters
New York, NY
Exchange
Nasdaq

Company profile sourced from SEC filings.

Corporate Insider Trades

Open-market purchases and sales by directors, officers, and other company insiders.

InsiderTypeValueDate
Naylor StuartCHIEF SCI OFCR, OPHTHALMOLOGYSell$294KOct 6, 2026
Forbes AlexandriaPRESIDENT & CEOSell$859KAug 18, 2026

Source: SEC EDGAR Form 4 filings

Congressional Trades

Recent disclosures by members of the U.S. House and Senate.

No recent congressional disclosures found for MGTX.

Source: Senate eFD and House Clerk STOCK Act disclosures

Get notable MGTX activity by email

Free alerts for the insider and congressional trades worth watching.

SMS is optional: we only save your number if you check the consent box and provide a valid number. Outside US/Canada, include + and your country code.

SMS Terms and Privacy Policy.

By submitting your email address, you will receive a free subscription to the MySmarTrend e-letter, and offers from us and our affiliates that we think might interest you. You can unsubscribe at any time. Privacy Policy.

For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.